QoL maintained with sasanlimab plus BCG in high-risk, BCG-naive NMIBC

Dr Bedke discusses quality of life data from the findings from the CREST Trial, which he presented at ASCO 2025.

Patient-reported outcomes (PROs) revealed that quality of life was preserved in patients receiving sasanlimab combined with bacillus Calmette-Guérin (BCG) compared to BCG alone in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC).

Despite statistically significant differences in some measures, none reached the threshold for clinical meaningfulness. Urinary symptoms and treatment-related discomfort remained comparable across treatment arms.

These findings support the use of sasanlimab with BCG, showing no detrimental impact on QoL while offering improved efficacy.